ʻO Rimegepant kahi mea hoʻopale mole liʻiliʻi o kacalcitoningene-related peptide (CGRP) receptor e ālai i ka hana a CGRP, he vasodilator potent i manaʻoʻiʻo e pāʻani i ka hana i ka migraine headache.Ua ʻae ʻia ʻo Rimegepant no ka mālama ʻana i nā hōʻeha migraine koʻikoʻi.I nā hoʻokolohua lapaʻau, ua ʻae maikaʻi ʻia ka rimegepant me nā manawa kakaikahi wale nō o ka piʻi ʻana o ka serum aminotransferase transient i ka wā o ka lāʻau lapaʻau a ʻaʻohe mea i hōʻike ʻia o ka hōʻeha ate.

ʻO Rimegepant kahi mea kū'ē waha o ka mea hoʻokipa CGRP i hoʻomohala ʻia e Biohaven Pharmaceuticals.Ua loaʻa iā ia ka ʻae FDA ma Pepeluali 27, 2020 no ka mālama ʻana i ka maʻi ʻeha o ka migraine.ʻOiai ua ʻae ʻia kekahi mau mea kūʻē makua o CGRP a me kāna mea loaʻa no ka migraine therapy (eg [erenumab], [fremanezumab], [galcanezumab]), rimegepant a me [ubrogepant] ʻo ia wale nō nā lālā o ka ʻohana "gepants" o nā lāʻau lapaʻau i koe i ka hoʻomohala ʻana, a ʻo ka CGRP antagonists wale nō i loaʻa ka bioavailability waha.ʻO ka maʻamau o kēia manawa o ka migraine therapy e pili ana i ka mālama ʻana i ka abortive me nā "triptans", e like me [sumatriptan], akā, ua contraindicated kēia mau lāʻau lapaʻau i nā poʻe maʻi me ka maʻi cerebrovascular a me ka maʻi cardiovascular ma mua o ko lākou mau waiwai vasoconstrictive.ʻO ka antagonism o ke ala CGRP ua lilo i mea hoihoi no ka migraine therapy no ka mea, ʻaʻole like me nā triptans, ʻaʻole i ʻike nā antagonists waha CGRP i nā waiwai vasoconstrictive a no laila ʻoi aku ka palekana no ka hoʻohana ʻana i nā maʻi me nā contraindications i ka lāʻau maʻamau.

ʻO Rimegepant kahiCalcitoninʻO Antagonist Peptide Receptor pili i nā Gene.ʻO ke ʻano hana o ka rimegepant e like me aCalcitoninʻO Antagonist Peptide Receptor pili i nā Gene.